Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-622 and Daratumumab Hyaluronidase-fihj in Relapsed or Refractory Multiple Myeloma
NCT05139225Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2021
- Primary completion
- Jul 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of maplirpacept in multiple myeloma (MM) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Incidence of dose-limiting toxicities at 28 days. Started Oct 2021; status: completed.
02
Drugs
maplirpacept
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05139225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139225.